Showing results (1431-1440 of 3,353) with videos related to

Sort By:
Pageof 336
Pharmacoeconomics|February 13, 2020
Ocrelizumab for Treating Patients with Primary Progressive Multiple Sclerosis: An Evidence Review Group Perspective of a NICE Single Technology AppraisalPeter Auguste, Jill Colquitt, Martin Connock, et al.
Pharmacoeconomics|December 10, 2019
Estimating Age- and Sex-Specific Utility Values from the CHU9D Associated with Child and Adolescent BMI z-ScoreAnagha Killedar, Thomas Lung, Stavros Petrou, et al.
Pharmacoeconomics|December 10, 2019
Preference-Based Health-Related Quality of Life Outcomes Associated with Preterm Birth: A Systematic Review and Meta-analysisStavros Petrou, Natnaree Krabuanrat, Kamran Khan
Pharmacoeconomics|January 11, 2020
Systematic Literature Review and Critical Appraisal of Health Economic Models Used in Cost-Effectiveness Analyses in Non-Alcoholic Steatohepatitis: Potential for ImprovementsPierre Johansen, Daniel Howard, Ryan Bishop, et al.
Pharmacoeconomics|November 27, 2014
Is there an economic rationale for cancer drugs to have a separate reimbursement review process for resource allocation purposes?Heather McDonald, Cathy Charles, Laurie Elit, et al.
Pharmacoeconomics|December 12, 2018
EQ-5D-5L Valuation for the Malaysian PopulationAsrul Akmal Shafie, Annushiah Vasan Thakumar, Ching Jou Lim, et al.
Pharmacoeconomics|August 30, 2017
The HTA Risk Analysis Chart: Visualising the Need for and Potential Value of Managed Entry Agreements in Health Technology AssessmentSabine Elisabeth Grimm, Mark Strong, Alan Brennan, et al.
Pharmacoeconomics|February 2, 2018
Treatment Preferences in Germany Differ Among Apheresis Patients with Severe HypercholesterolemiaAxel C Mühlbacher, Andrew Sadler, Franz-Werner Dippel, et al.
Pharmacoeconomics|January 22, 2018
The Relative Importance of Clinical, Economic, Patient Values and Feasibility Criteria in Cancer Drug Reimbursement in Canada: A Revealed Preferences Analysis of Recommendations of the Pan-Canadian Oncology Drug Review 2011-2017Chris Skedgel, Dominika Wranik, Min Hu
Pharmacoeconomics|December 17, 2017
The French National Authority for Health (HAS) Guidelines for Conducting Budget Impact Analyses (BIA)Salah Ghabri, Erwan Autin, Anne-Isabelle Poullié, et al.
Pageof 336